Social Media Ideas for Merck

<![CDATA[Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal]]>

<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>

Pharma giant Merck to slash 54 jobs at Rahway headquarters

The pharmaceutical company Merck & Co. has notified state officials that it will lay off 54 workers at its Rahway headquarters, according to a September filing with the New Jer...

<![CDATA[Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch]]>

The Merck/Moderna Results

The Merck/Moderna Results Anonymous (not verified) Fri, 10/23/2026 - 13:17 pharmagather item url The Merck/Moderna Results pharmagather...

Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

Merck reveals study success, and possible safety worries, for eye drug hopeful

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate...

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer the...

Merck KGaA to buy Silence Therapeutics in all-cash deal

Merck KGaA to acquire Silence Therapeutics for $1.3 billion

Merck’s new BioReliance® Facility in Darmstadt: supporting biologics development and commercialization in Europe

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability studies in Europe. The post Merck’s new BioReliance® Faci...

Merck Commits $2.9 Billion to Pennsylvania Vaccine and Drug Sites

Merck plans a $2.9 billion Pennsylvania expansion through 2030, including $550 million for West Point and Spring House research facilities.

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture...

Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications. The pos...

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...

Merck KGaA bets on RNAi with $1.3B Silence buyout

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

<![CDATA[Simcere Zaiming Licenses Sim0660 to Roche for $1.53 billion]]>

<![CDATA[Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Lilly adds to immune drug pipeline with $2.9B Merida buyout

The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida...

<![CDATA[Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targ...